Kazia Therapeutics Limited
KZIA
$6.75
$0.172.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -2.67% | -86.84% | |||
| Total Revenue | -2.67% | -99.08% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -2.67% | -99.08% | |||
| SG&A Expenses | -2.75% | -42.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | -56.72% | |||
| Operating Income | 2.75% | 51.35% | |||
| Income Before Tax | 2.75% | 40.48% | |||
| Income Tax Expenses | 2.64% | -1.79% | |||
| Earnings from Continuing Operations | 2.75% | 40.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | 40.80% | |||
| EBIT | 2.75% | 51.35% | |||
| EBITDA | 2.75% | 54.01% | |||
| EPS Basic | 2.75% | 59.96% | |||
| Normalized Basic EPS | 2.75% | 57.56% | |||
| EPS Diluted | 2.75% | 59.95% | |||
| Normalized Diluted EPS | 2.75% | 57.56% | |||
| Average Basic Shares Outstanding | 0.00% | 47.85% | |||
| Average Diluted Shares Outstanding | 0.00% | 54.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||